Cache DNA

Executive Summary

Cache DNA is pioneering next-generation biopreservation technology that enables DNA, RNA, and other biomolecules to be stored at ambient temperatures for extended periods, eliminating the need for costly and logistically complex cold-chain storage. By preserving nucleic acid integrity without refrigeration, the company aims to democratize access to high-quality biospecimens for research and diagnostics, thereby accelerating advances in genomics and personalized medicine. Founded in 2021 and headquartered in San Francisco, Cache DNA addresses a critical bottleneck in the life sciences: the scalability and accessibility of biological sample storage. Its platform has the potential to reduce storage costs significantly, expand the reach of genomic testing to underserved regions, and improve the reliability of diagnostic assays that rely on preserved nucleic acids. Though still in early stages, Cache DNA operates in a rapidly growing market driven by the expansion of genomic data and precision medicine. The company has yet to disclose funding or partnerships, but its technology holds promise for biobanks, clinical labs, and pharmaceutical companies. Key near-term milestones include validation studies, pilot partnerships, and likely a Series A fundraising round. The main risk lies in the technical challenge of maintaining long-term stability at ambient conditions and competition from established cold-chain and alternative preservation methods. Overall, Cache DNA represents a compelling investment opportunity in the biopreservation space, but conviction is tempered by the early stage and lack of public data.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2027Partnership with Major Biobank or Diagnostic Company40% success
• Q3 2026Publication of Peer-Reviewed Validation Study60% success